Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2011 - 2026)

Neurocrine Biosciences (NBIX) has reported Long-Term Deferred Tax for 8 consecutive years, with $8.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Deferred Tax fell 98.34% year-over-year to $8.9 million; the trailing twelve-month figure through Jun 2026 stood at $8.9 million (down 98.34% YoY), and the FY2025 full-year result was $320.3 million, down 34.05% from the prior year.
• Long-Term Deferred Tax slipped to $8.9 million in Q2 2026 per NBIX's latest filing, from $381.4 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $536.8 million in Q2 2025 and bottomed at $8.9 million in Q2 2026.
• Historically, Long-Term Deferred Tax has averaged $366.3 million across 5 years, with a median of $373.3 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Long-Term Deferred Tax surged 33.95% in 2024, then slumped 98.34% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $305.9 million in 2022, then grew by 18.54% to $362.6 million in 2023, then soared by 33.95% to $485.7 million in 2024, then plunged by 34.05% to $320.3 million in 2025, then plunged by 97.22% to $8.9 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $8.9 million, $381.4 million, and $320.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.